| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 4,151 | 3,432 | +20.9% |
| EBITDA | 291 | 309 | −5.7% |
| EBITDA margin | 7.0% | 9.0% | −2.0 pts |
| Profit before tax | 152 | 246 | −38.0% |
| Net profit | 106 | 159 | −33.4% |
| EPS | ₹6.72 | ₹10.14 | −33.7% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 14,281 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 470 | 369 | 620 | 343 | 450 | ||
| 22.4 | 20.9 | 0.0 | — | — | ||
| 2,812 | 2,812 | 2,408 | 2,083 | 1,633 | ||
| 16,646 | — | — | — | — | ||
| 15,312 | 14,264 | 12,741 | 11,431 | 12,080 | ||
| — | +12.0% | +11.5% | −5.4% | — | ||
| 1,513 | 1,497 | 1,330 | 991 | 1,606 | ||
| 9.9% | 10.5% | 10.4% | 8.7% | 13.3% | ||
| 981 | 995 | 920 | 688 | 1,346 | ||
| 1,383 | 856 | 604 | 447 | 911 | ||
| 9.0% | 6.0% | 4.7% | 3.9% | 7.5% | ||
| ₹88.06 | ₹54.45 | ₹38.55 | ₹28.52 | ₹58.11 | ||
| — | +41.2% | +35.2% | −50.9% | — | ||
| — | 1,234 | 1,128 | 794 | 1,296 | ||
| — | −887 | −859 | −1,319 | −1,804 | ||
| 346 | 346 | 269 | −525 | −507 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 14,280.7 | |
| - Cash, Equiv & ST Investments | 450.2 | 343.2 | 619.9 | 368.8 | 469.5 | |
| + Minority Interest | — | — | 0.0 | 20.9 | 22.4 | |
| + Total Debt | 1,633.0 | 2,082.6 | 2,408.2 | 2,812.5 | 2,812.5 | |
| Enterprise Value | — | — | — | — | 16,646.0 | |
| Revenue | 12,079.5 | 11,431.3 | 12,741.3 | 14,263.9 | 15,311.8 | |
| Growth %, YoY | — | -5.4 | +11.5 | +12.0 | — | |
| EBITDA | 1,606.4 | 990.7 | 1,330.3 | 1,497.3 | 1,512.6 | |
| Margin % | 13.30 | 8.67 | 10.44 | 10.50 | 9.88 | |
| EBIT | 1,346.3 | 687.8 | 920.1 | 995.0 | 981.5 | |
| Net Income | 910.8 | 447.1 | 604.3 | 856.0 | 1,382.6 | |
| Margin % | 7.54 | 3.91 | 4.74 | 6.00 | 9.03 | |
| EPS, Adj (current shares) | 58.11 | 28.52 | 38.55 | 54.45 | 88.06 | |
| Growth %, YoY | — | -50.9 | +35.2 | +41.2 | — | |
| Cash from Operations | 1,296.3 | 793.8 | 1,127.8 | 1,233.8 | — | |
| Capital Expenditures | -1,803.8 | -1,318.5 | -858.8 | -887.3 | — | |
| Free Cash Flow | -507.4 | -524.7 | 269.0 | 346.5 | 346.5 | |
Prices at the 30 October 2026 close · figures from the company's filings with NSE
DCM Shriram (NSE: DCMSHRIRAM) had a market capitalisation of ₹13,630 crore at the 30 October 2026 close (₹874.00 a share), a PE ratio of 9.9 on the last four quarters' profit and a price-to-book ratio of 1.61. In FY26 its consolidated net profit attributable to shareholders was ₹853 crore on revenue of ₹14,264 crore; in Q2 FY27 (July–September 2026) it was ₹105 crore, down 33.7% year on year. Its debt-to-equity ratio was 0.22 on 30 September 2026. Promoters held 66.52% of the shares on 30 September 2026.
DCM Shriram's PE ratio is 9.9 at the 30 October 2026 close (₹874.00 a share): a market capitalisation of ₹13,630 crore divided by consolidated net profit attributable to shareholders of ₹1,380 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹853 crore) it is 16.0.
DCM Shriram's price-to-book (PB) ratio is 1.61 at the 30 October 2026 close: a market capitalisation of ₹13,630 crore divided by shareholders' equity (book value) of ₹8,445 crore on 30 September 2026. That is a book value of ₹541.54 per share against a share price of ₹874.00.
DCM Shriram's net worth — shareholders' equity in its consolidated balance sheet — was ₹8,445 crore on 30 September 2026, up 16.9% from ₹7,225 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹13,630 crore at the 30 October 2026 close.
DCM Shriram's market capitalisation was ₹13,630 crore at the 30 October 2026 close: 15.6 crore shares at ₹874.00 each.
No. DCM Shriram had borrowings of ₹1,893 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.22. Its cash and current investments were ₹1,000 crore, so its net debt was ₹892 crore.
DCM Shriram's basic earnings per share (EPS) were ₹54.73 in FY26, against ₹38.75 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹88.74.
DCM Shriram's debt-to-equity ratio was 0.22 on 30 September 2026: borrowings of ₹1,893 crore against total equity of ₹8,468 crore. A year earlier, on 30 September 2025, it was 0.28.
DCM Shriram's book value per share was ₹541.54 on 30 September 2026: shareholders' equity of ₹8,445 crore divided by the 15.6 crore shares in issue, up 17.5% from ₹460.93 a year earlier. The share price at the 30 October 2026 close was ₹874.00.
Promoters held 66.52% of DCM Shriram on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
In FY26, DCM Shriram's return on equity (ROE) was 11.6% and its return on capital employed (ROCE) was 10.0%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 8.9% and ROCE 10.1%.
DCM Shriram's dividend yield is 1.74% at the 30 October 2026 close: dividends of ₹15.20 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹874.00. They were ₹4 on 30 October 2026 (interim), ₹4 on 31 July 2026, ₹3.60 on 23 January 2026 (interim) and ₹3.60 on 3 November 2025 (interim).
On 30 September 2026, DCM Shriram's shares were held by promoters 66.52%, foreign portfolio investors (FII/FPI) 3.98%, domestic institutions (DII) 8.32% (including mutual funds at 1.31%) and retail and other non-institutional investors 20.50%. Over the year, FII holding was up 0.01 percentage points from 3.97% and DII holding was up 0.07 percentage points from 8.25%.
In 2026, DCM Shriram has declared three dividends totalling ₹11.60 a share: ₹3.60 (interim) with record date 24 January 2026 and ex-date 23 January 2026, ₹4 with record date 31 July 2026 and ₹4 (interim) with record date 30 October 2026.
DCM Shriram's latest results are for Q2 FY27 (July–September 2026), filed on 26 October 2026: consolidated net profit attributable to shareholders ₹105 crore, down 33.7% from ₹158 crore in Q2 FY26; revenue from operations ₹4,151 crore, up 20.9% year on year.
In FY26 (April 2025–March 2026), DCM Shriram's consolidated net profit attributable to shareholders was ₹853 crore, up 41.2% from ₹604 crore in FY25, on revenue from operations of ₹14,264 crore (up 12.0%). Over three years, from FY23, net profit was down 6.3%.
In FY26, DCM Shriram generated ₹1,234 crore of cash from operations and spent ₹887 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹346 crore. In FY25 it was ₹269 crore.
DCM Shriram has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
At the 30 October 2026 closing prices, on FY26 net profit attributable to shareholders, DCM Shriram's PE ratio is 16.0, the third highest of the four: Gujarat Narmada Valley Fertilizers and Chemicals 9.2, Triveni Engineering & Industries 18.5 and TTK Healthcare 19.5, a peer average of 15.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
On FY26 consolidated figures, against Gujarat Narmada Valley Fertilizers and Chemicals, Triveni Engineering & Industries and TTK Healthcare: DCM Shriram's operating margin of 7.0% is the second highest of the four (Gujarat Narmada Valley Fertilizers and Chemicals 7.4%, Triveni Engineering & Industries 5.3%, TTK Healthcare 2.0%; peer average 4.9%); its return on equity of 11.6% is the highest of the four (Gujarat Narmada Valley Fertilizers and Chemicals 9.1%, Triveni Engineering & Industries 8.3%, TTK Healthcare 6.0%; peer average 7.8%); its revenue growth over three years of 5.7% a year is the third highest of the four (Gujarat Narmada Valley Fertilizers and Chemicals −8.7% a year, Triveni Engineering & Industries 6.5% a year, TTK Healthcare 5.7% a year; peer average 1.2% a year).
In FY26, DCM Shriram earned net profit attributable to shareholders of ₹853 crore on revenue of ₹14,264 crore, against ₹808 crore on ₹7,773 crore for Gujarat Narmada Valley Fertilizers and Chemicals. DCM Shriram's operating margin was 7.0% (Gujarat Narmada Valley Fertilizers and Chemicals 7.4%) and its return on equity 11.6% (Gujarat Narmada Valley Fertilizers and Chemicals 9.1%). At the 30 October 2026 close, DCM Shriram's market capitalisation was ₹13,630 crore against ₹7,418 crore for Gujarat Narmada Valley Fertilizers and Chemicals, and its PE ratio on FY26 profit 16.0 against 9.2.
From DCM Shriram's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 30 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.